MA41315A - Composés co-agonistes de gip et de glp-1 - Google Patents

Composés co-agonistes de gip et de glp-1

Info

Publication number
MA41315A
MA41315A MA041315A MA41315A MA41315A MA 41315 A MA41315 A MA 41315A MA 041315 A MA041315 A MA 041315A MA 41315 A MA41315 A MA 41315A MA 41315 A MA41315 A MA 41315A
Authority
MA
Morocco
Prior art keywords
gip
glp
agonist compounds
compounds
incretinimetic
Prior art date
Application number
MA041315A
Other languages
English (en)
Other versions
MA41315B1 (fr
Inventor
Jorge Alsina-Fernandez
Bengt Krister Bokvist
Tamer Coskun
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41315A publication Critical patent/MA41315A/fr
Publication of MA41315B1 publication Critical patent/MA41315B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés incrétino-mimétiques duels qui sont des agonistes des récepteurs humains à la fois du gip (glucose-dependent insulinotropic polypeptide) et du glp-1 (glucagon-like peptide-1), et qui peuvent être utilisés pour traiter le diabète sucré de type 2 (t2d).
MA41315A 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1 MA41315B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1

Publications (2)

Publication Number Publication Date
MA41315A true MA41315A (fr) 2017-11-15
MA41315B1 MA41315B1 (fr) 2019-11-29

Family

ID=55315708

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41315A MA41315B1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1

Country Status (45)

Country Link
US (1) US9474780B2 (fr)
EP (2) EP3597662A1 (fr)
JP (3) JP6219534B2 (fr)
KR (4) KR102330764B1 (fr)
CN (2) CN112608377B (fr)
AR (1) AR103242A1 (fr)
AU (1) AU2016205435B2 (fr)
CA (1) CA2973352C (fr)
CL (1) CL2017001760A1 (fr)
CO (1) CO2017006737A2 (fr)
CR (1) CR20170310A (fr)
CY (1) CY1122028T1 (fr)
DK (1) DK3242887T3 (fr)
DO (1) DOP2017000153A (fr)
EA (3) EA035055B1 (fr)
EC (1) ECSP17043648A (fr)
ES (1) ES2747928T3 (fr)
FI (1) FIC20230005I1 (fr)
FR (1) FR23C1006I2 (fr)
HR (1) HRP20191614T1 (fr)
HU (2) HUE045860T2 (fr)
IL (3) IL252499B (fr)
JO (2) JOP20200119A1 (fr)
LT (2) LT3242887T (fr)
MA (2) MA41315B1 (fr)
MD (1) MD3242887T2 (fr)
ME (1) ME03494B (fr)
MX (2) MX2017008927A (fr)
MY (1) MY193616A (fr)
NL (1) NL301217I2 (fr)
NO (1) NO2023005I1 (fr)
NZ (1) NZ732000A (fr)
PE (1) PE20170954A1 (fr)
PH (1) PH12017501252A1 (fr)
PL (1) PL3242887T3 (fr)
PT (1) PT3242887T (fr)
RS (1) RS59146B1 (fr)
SG (1) SG11201705603YA (fr)
SI (1) SI3242887T1 (fr)
SV (1) SV2017005453A (fr)
TN (1) TN2017000198A1 (fr)
TW (1) TWI582109B (fr)
UA (1) UA118239C2 (fr)
WO (1) WO2016111971A1 (fr)
ZA (1) ZA201703930B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212180A1 (fr) 2013-12-18 2023-07-19 The Scripps Research Institute Agents thérapeutiques modifiés, conjugués lipidiques peptidiques agrafés et compositions associées
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3551202B1 (fr) 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'efficacité de médicaments à base d'incrétine chez les sujets en ayant besoin
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3624828A4 (fr) 2017-05-18 2021-03-03 Merck Sharp & Dohme Corp. Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
ES2961384T3 (es) * 2018-05-04 2024-03-11 Novo Nordisk As Derivados de GIP y usos de los mismos
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CA3107108A1 (fr) 2018-07-23 2020-01-30 Eli Lilly And Company Procede d'utilisation d'un co-agoniste de gip/glp1 contre le diabete
MY197569A (en) * 2018-07-23 2023-06-25 Lilly Co Eli Gip/glp1 co-agonist compounds
JP2021533094A (ja) * 2018-07-23 2021-12-02 イーライ リリー アンド カンパニー 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
EP3856339A1 (fr) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip et leurs utilisations
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
EP3983432A1 (fr) 2019-06-12 2022-04-20 Askgene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
WO2021034815A1 (fr) 2019-08-19 2021-02-25 Eli Lilly And Company Procédés de fabrication d'analogues d'incrétine
KR20210040818A (ko) 2019-10-04 2021-04-14 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3165430A1 (fr) 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Composes co-agonistes de gip/glp1
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CA3184717A1 (fr) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonistes au niveau des recepteurs de glp-1 et de gip appropries pour une administration par voie orale
EP4185606A1 (fr) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonistes de récepteurs de glp-1 et de gip
CN115925994B (zh) * 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
TW202229323A (zh) 2020-10-17 2022-08-01 印度商太陽製藥工業有限公司 新型glp-1/gip雙重促效劑
EP4257597A1 (fr) * 2020-12-02 2023-10-11 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Composés polypeptidiques modifiés par lactame
MX2023008330A (es) * 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
CN116867505A (zh) 2021-02-17 2023-10-10 伊莱利利公司 替西帕肽治疗方法
EP4294423A1 (fr) * 2021-02-17 2023-12-27 Eli Lilly and Company Procédés thérapeutiques agonistes doubles gip/glp1
EP4317179A1 (fr) 2021-03-25 2024-02-07 BrightGene Bio-Medical Technology Co., Ltd. Agoniste du récepteur double gip et glp-1, composition pharmaceutique et utilisation
JP2024518058A (ja) 2021-05-07 2024-04-24 イーライ リリー アンド カンパニー 浸食性錠剤
AU2022283413B2 (en) * 2021-05-28 2024-05-02 Guangdong Raynovent Biotech Co., Ltd. Preparation and application of polypeptide
WO2022253202A1 (fr) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
TW202302624A (zh) * 2021-06-18 2023-01-16 大陸商廣東眾生睿創生物科技有限公司 含內醯胺橋的多肽化合物
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists
AU2022347024A1 (en) * 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
WO2023089594A1 (fr) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (fr) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 Utilisation pharmaceutique de polypeptide dans la préparation de médicaments pour le traitement et/ou la prévention du diabète et de l'obésité et de maladies associées
EP4299052A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
WO2024006662A1 (fr) 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024020388A1 (fr) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
WO2024050289A1 (fr) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions pour administration orale
WO2024059674A1 (fr) * 2022-09-15 2024-03-21 Eli Lilly And Company Composés agonistes doubles de gip et de glp-1
WO2024061310A1 (fr) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 Composition pharmaceutique à base de double agoniste des récepteurs glp-1 et gip et utilisation correspondante
WO2024077149A2 (fr) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides pour la synthèse d'incrétine
WO2024098718A1 (fr) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 Nouveau composé polypeptidique à action prolongée, composition et utilisation associée
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2323678B1 (fr) * 2008-08-07 2016-03-23 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
EP2376097A4 (fr) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Promédicaments peptidiques de la superfamille du glucagon à base d'amide
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
AU2011348202A1 (en) * 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
WO2012171994A1 (fr) 2011-06-15 2012-12-20 Novo Nordisk A/S Insulines à substitutions multiples
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
MX2014007120A (es) * 2011-12-23 2015-03-05 Boehringer Ingelheim Int Analogos de glucagon.
TR201815338T4 (tr) * 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina

Also Published As

Publication number Publication date
JOP20200119A1 (ar) 2017-06-16
MD3242887T2 (ro) 2019-11-30
CY1122028T1 (el) 2020-10-14
ES2747928T3 (es) 2020-03-12
NZ732000A (en) 2018-11-30
PL3242887T3 (pl) 2020-02-28
IL252499A0 (en) 2017-07-31
EA202090392A2 (ru) 2020-05-31
AU2016205435A1 (en) 2017-06-08
IL252499B (en) 2020-08-31
NL301217I2 (nl) 2023-04-04
NZ748274A (en) 2022-03-25
FR23C1006I1 (fr) 2023-03-24
RS59146B1 (sr) 2019-09-30
TN2017000198A1 (en) 2018-10-19
IL276492B (en) 2021-04-29
KR20170092661A (ko) 2017-08-11
ME03494B (fr) 2020-01-20
EA031591B1 (ru) 2019-01-31
SV2017005453A (es) 2018-08-27
JP6219534B2 (ja) 2017-10-25
CR20170310A (es) 2017-08-17
CL2017001760A1 (es) 2018-03-16
IL281545A (en) 2021-05-31
EP3242887B1 (fr) 2019-08-14
HRP20191614T1 (hr) 2019-12-13
MA50422A (fr) 2020-08-26
EA035055B1 (ru) 2020-04-22
EP3242887A1 (fr) 2017-11-15
EA202090392A3 (ru) 2020-08-31
LTPA2023504I1 (fr) 2023-02-27
LT3242887T (lt) 2019-11-11
CO2017006737A2 (es) 2017-09-29
JP6545766B2 (ja) 2019-07-17
EA201791281A1 (ru) 2017-11-30
PT3242887T (pt) 2019-10-29
US20160199438A1 (en) 2016-07-14
MX2021005835A (es) 2021-07-15
WO2016111971A1 (fr) 2016-07-14
MX2017008927A (es) 2017-10-11
NO2023005I1 (no) 2023-02-02
TWI582109B (zh) 2017-05-11
HUS2300006I1 (hu) 2023-02-28
SI3242887T1 (sl) 2019-10-30
IL276492A (en) 2020-09-30
UA118239C2 (uk) 2018-12-10
JP2018052933A (ja) 2018-04-05
CN112608377B (zh) 2024-02-13
KR20210145311A (ko) 2021-12-01
KR20190026967A (ko) 2019-03-13
EA201892057A1 (ru) 2019-02-28
CN107207576A (zh) 2017-09-26
CN107207576B (zh) 2020-11-24
AU2016205435B2 (en) 2018-03-29
CA2973352C (fr) 2019-03-26
CA2973352A1 (fr) 2016-07-14
JP6754867B2 (ja) 2020-09-16
HUE045860T2 (hu) 2020-01-28
ZA201703930B (en) 2019-06-26
ECSP17043648A (es) 2017-11-30
MY193616A (en) 2022-10-20
EP3597662A1 (fr) 2020-01-22
CN112608377A (zh) 2021-04-06
JP2019203000A (ja) 2019-11-28
TW201636362A (zh) 2016-10-16
AR103242A1 (es) 2017-04-26
NL301217I1 (fr) 2023-02-15
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
DK3242887T3 (da) 2019-09-02
BR112017010596A2 (pt) 2018-03-06
MA41315B1 (fr) 2019-11-29
FR23C1006I2 (fr) 2024-01-05
JP2017507124A (ja) 2017-03-16
JO3575B1 (ar) 2020-07-05
SG11201705603YA (en) 2017-08-30
FIC20230005I1 (fi) 2023-02-02
KR20230023822A (ko) 2023-02-17
PE20170954A1 (es) 2017-07-13
DOP2017000153A (es) 2017-07-15
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
MA41315A (fr) Composés co-agonistes de gip et de glp-1
MY197569A (en) Gip/glp1 co-agonist compounds
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
IL279224A (en) 1-GLP agonist receptors and their use
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
HUE063074T2 (hu) GLP-1 receptor agonisták és alkalmazásuk
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
NZ740644A (en) Glucagon receptor agonists
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
MX2022001137A (es) Compuestos agonistas de gipr.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA202191379A1 (ru) Комбинированное лечение nafld и nash
EP4043026A4 (fr) Glucagon, composition comprenant un agoniste double du récepteur de glp-1 et du récepteur de gip et utilisation thérapeutique associée
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1